2 TOWER PL, SOUTH SAN FRANCISCO, CA 94080

Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

Retrieved on: 
Monday, March 25, 2024
Survival, Verge, ALS, Caregiver, Social justice, Partnership, Patient, SAN, Tissue, News, Business development, Ferrer, POC, Neuron, B Corporation (certification), Clinical trial, Genomics, DSM-IV codes, Drug development, Safety, CONVERGE, Pharmaceutical industry

VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.

Key Points: 
  • VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, Verge’s all-in-human, AI-powered platform.
  • Under the terms of the agreement, Ferrer will obtain the exclusive rights to co-develop and commercialize VRG50635 for ALS in multiple regions outside of the United States of America.
  • Verge has retained all rights to development and commercialization for VRG50635 for all uses in the United States and all countries outside the agreement.
  • “We're thrilled to work with Ferrer to progress VRG50635 through clinical development and towards potential commercialization.

Verge Genomics to Present at Evercore ISI 2024 Emerging Biotech Conference

Retrieved on: 
Wednesday, February 21, 2024
SAN, EST, Drug discovery, Genomics, Artificial intelligence, Conference

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, announced today that Verge Co-founder and CEO Alice Zhang will present at the virtual Evercore ISI 2024 Emerging Biotech Conference, on Wednesday, February 28th from 10:45 a.m. – 11:15 a.m. EST.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, announced today that Verge Co-founder and CEO Alice Zhang will present at the virtual Evercore ISI 2024 Emerging Biotech Conference, on Wednesday, February 28th from 10:45 a.m. – 11:15 a.m. EST.

Verge Genomics Announces Initiation of Proof-of-Concept Study for the Treatment of Amyotrophic Lateral Sclerosis (ALS) with VRG50635

Retrieved on: 
Tuesday, January 9, 2024
Artificial intelligence, Patient, ALS, SAN, Verge, Tissue, FAAN, Drug discovery, Genomics, Disease, Safety, Therapy, Research, Health care

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, today announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The study will assess the safety and tolerability of escalating doses of VRG50635, a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, the company’s all-in-human, AI-powered platform. VRG50635 is one of the first drugs to enter the clinic that was entirely discovered and developed from an AI-enabled platform.

Key Points: 
  • The study will assess the safety and tolerability of escalating doses of VRG50635, a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, the company’s all-in-human, AI-powered platform.
  • VRG50635 is one of the first drugs to enter the clinic that was entirely discovered and developed from an AI-enabled platform.
  • In contrast, Verge's study harnesses the power of digital devices to collect thousands of objective, quantitative, relevant measurements directly from the patient, including mobility, breathing, and sleeping all from the comfort of their home.
  • “Incorporating cutting-edge technology into our ALS proof-of-concept study is a necessity born from the urgent unmet need to efficiently study promising therapeutics for people battling this devastating disease.

Verge Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024

Retrieved on: 
Wednesday, January 3, 2024
Conference, Genomics, Gateway, Drug discovery, Artificial intelligence, SAN, Westin Hotels & Resorts

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, announced today that Verge Genomics’ co-founder and CEO, Alice Zhang, will present at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, announced today that Verge Genomics’ co-founder and CEO, Alice Zhang, will present at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Alice will provide an overview of Verge and recent corporate milestones on Thursday, January 11th, at 11:30 AM PT in the Golden Gate room (32nd Floor) of The Westin Hotel in San Francisco, CA.

Verge Genomics Will Use Modality.AI in Its ALS Phase 1b Clinical Trial of Its Lead Drug Candidate VRG50635

Retrieved on: 
Wednesday, November 29, 2023
Emerald, Walking, Partnership, Drug discovery, ALS, Probability, Drug development, Translational medicine, POC, SAN, Genomics, Speech, Modality, Artificial intelligence, Smartphone, Biomarker, Machine learning, Publication, Patient, Data collection, Communication, Medical imaging

VRG50635 is a potential best-in-class small molecule inhibitor of PIKfyve that is in clinical development for amyotrophic lateral sclerosis (ALS) and is expected to move into Phase 1b in the coming months.

Key Points: 
  • VRG50635 is a potential best-in-class small molecule inhibitor of PIKfyve that is in clinical development for amyotrophic lateral sclerosis (ALS) and is expected to move into Phase 1b in the coming months.
  • “Endpoints used in ALS trials are often subjective, biased, and only limited objective biomarkers of neurological function are available.
  • The collaboration with Modality.AI builds on Verge’s efforts to enhance how patient data will be collected in its Phase 1b study for VRG50635.
  • VRG50635 completed a Phase 1 single- and multiple-ascending dose clinical trial in healthy volunteers in June 2023.

Verge Genomics and the Pritzker Neuropsychiatric Disorders Research Consortium Form Cutting Edge Schizophrenia Research Collaboration

Retrieved on: 
Tuesday, October 31, 2023
Genomics, University of California, Irvine Medical Center, Stanford University, CONVERGE, Neuro, Hallucination, Neuroanatomy, Deficit spending, Research, University, Artificial intelligence, Weill Cornell Medicine, Drug discovery, Partnership, DSM-IV codes, Delusion, Cornell University, Patient, Diagnosis, SAN, Pharmaceutical industry, Medical device, Schizophrenia, Biotechnology

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced that it has entered into a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium to further the company’s cutting-edge research on schizophrenia.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence and human data, today announced that it has entered into a collaboration with the Pritzker Neuropsychiatric Disorders Research Consortium to further the company’s cutting-edge research on schizophrenia.
  • By combining their respective strengths and resources, Verge Genomics and the Pritzker Consortium aim to make substantial strides in the field of schizophrenia research.
  • "We are thrilled to embark on this transformative journey alongside Verge Genomics, combining their AI-powered CONVERGE platform with the invaluable resources of the Pritzker Neuropsychiatric Disorders Research Consortium.
  • This includes the Pritzker Brain Bank, known for stringent subject selection and comprehensive metadata, coupled with deep expertise in human structural and functional neuroanatomy,” said Richard M. Myers, Ph.D., Co-Project Leader, Pritzker Neuropsychiatric Disorders Research Consortium.

Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases

Retrieved on: 
Friday, September 8, 2023
Probability, Senior, Genomics, CNS, AstraZeneca, Eli Lilly, Patient, Machine learning, Drug discovery, Artificial intelligence, Alexion, Rare, ALS, Pharmaceutical industry, Research

SOUTH SAN FRANCISCO, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence (AI) and patient tissue data, today announced a multi-target collaboration with Alexion, AstraZeneca Rare Disease ("Alexion") to identify novel drug targets for rare neurodegenerative and neuromuscular diseases. Under the terms of the four-year agreement, Verge will receive up to $42 million, consisting of upfront fee, equity, and near-term payments, with a potential deal value of $840 million plus potential downstream royalties.

Key Points: 
  • Verge to receive up to $42M in upfront and near-term payments, with future cumulative milestones worth up to $840M
    SOUTH SAN FRANCISCO, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery using artificial intelligence (AI) and patient tissue data, today announced a multi-target collaboration with Alexion, AstraZeneca Rare Disease ("Alexion") to identify novel drug targets for rare neurodegenerative and neuromuscular diseases.
  • Under the terms of the four-year agreement, Verge will receive up to $42 million, consisting of upfront fee, equity, and near-term payments, with a potential deal value of $840 million plus potential downstream royalties.
  • Alexion will select high-potential targets for each indication, with the option to license and advance successful targets through clinical development and commercialization.
  • “Our collaboration with Alexion is a tremendous opportunity to leverage the combined power of CONVERGE’s technology-enabled approach to drug discovery with Alexion’s expertise in developing and commercializing rare disease treatments,” said Jane Rhodes, Chief Business Officer, Verge Genomics.